| advertise add site services publishers database health videos | ![]() | about toolbar stats live show health store more stuff JOIN/LOGIN |
Fibrates for treatment of the metabolic syndrome - Metabolic Syndrome... metabolic-syndrome-instit... | Fibrates - Dosing table globalrph.com | Fibrates for treatment of the metabolic syndrome - Metabolic Syndrome... metabolicsyndromeinstitut... | Fibrates for treatment of the metabolic syndrome - Metabolic Syndrome... metabolicsyndromeinstitut... |
In pharmacology, the fibrates are a class of amphipathic carboxylic acids. They are used for a range of metabolic disorders, mainly hypercholesterolemia (high cholesterol), and are therefore hypolipidemic agents.
[edit] MembersFibrates prescribed commonly are:
[edit] IndicationsFibrates are used in accessory therapy in many forms of hypercholesterolemia, usually in combination with statins.[1] Clinical trials do support their use as monotherapy agents. Fibrates reduce the number of non-fatal heart attacks, but do not improve all-cause mortality and are therefore only indicated in those not tolerant to statins.[2] Although less effective in lowering LDL, fibrates improve HDL and triglyceride levels by increasing HDL levels and decreasing triglyceride levels, and seem to improve insulin resistance when the dyslipidemia is associated with other features of the metabolic syndrome (hypertension and diabetes mellitus type 2). They are therefore used in many hyperlipidemias. [edit] MechanismFibrates are agonists of the PPAR-α receptor[3] in muscle, liver, and other tissues. Activation of PPAR-α signaling results in:
[edit] Side effectsMost fibrates can cause mild stomach upset and myopathy (muscle pain with CPK elevations). Since fibrates increase the cholesterol content of bile, they increase the risk for gallstones. In combination with statin drugs, fibrates cause an increased risk of rhabdomyolysis, idiosyncratic destruction of muscle tissue, leading to renal failure. A powerful statin drug, cerivastatin (Lipobay), was withdrawn because of this complication. The less lipophilic statins are less prone to cause this reaction, and are probably safer when combined with fibrates. [edit] PharmacologyAlthough used clinically since the 1930s,[4] if not earlier, the mechanism of action of fibrates remained unelucidated until, in the 1990s, it was discovered that fibrates activate PPAR (peroxisome proliferator-activated receptors), especially PPARα. The PPARs are a class of intracellular receptors that modulate carbohydrate and fat metabolism and adipose tissue differentiation. Activating PPARs induces the transcription of a number of genes that facilitate lipid metabolism. Fibrates are structurally and pharmacologically related to the thiazolidinediones, a novel class of anti-diabetic drugs that also act on PPARs (more specifically PPARγ) Fibrates are a substrate of (metabolized by) CYP3A4.[5] [edit] See also[edit] References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ↑ top of page ↑ | about thumbshots |